PRESS RELEASE published on 03/30/2026 at 08:30, 4 months 16 days ago NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer NANOBIOTIX announces first data from phase 2 trial on JNJ-1900 for stage 3 lung cancer presented by Johnson & Johnson at European Lung Cancer Conference Phase 2 Trial NANOBIOTIX Lung Cancer Johnson & Johnson JNJ-1900
BRIEF published on 03/26/2026 at 21:20, 4 months 19 days ago NANOBIOTIX to Release 2025 Financial Results and Update Conference Call Biotechnology Market Update 2025 Financial Results Nanoparticle Treatments
BRIEF published on 03/26/2026 at 21:20, 4 months 19 days ago Nanobiotix Announces the Publication of its 2025 Annual Results Financial Results Biotechnology NANOBIOTIX Online Conference Nanoparticles
BRIEF published on 03/26/2026 at 21:20, 4 months 19 days ago NANOBIOTIX publiera ses résultats financiers et sa mise à jour pour 2025 Biotechnologie Conférence Téléphonique Mise À Jour Du Marché Résultats Financiers 2025 Traitements Par Nanoparticules
BRIEF published on 03/26/2026 at 21:20, 4 months 19 days ago Nanobiotix Annonce la Publication de Ses Résultats Annuels 2025 Résultats Financiers Biotechnologie NANOBIOTIX Nanoparticules Conférence En Ligne
PRESS RELEASE published on 03/26/2026 at 21:15, 4 months 19 days ago NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2025 le 31 mars 2026 NANOBIOTIX publiera ses résultats financiers et opérationnels de l'exercice 2025 le 31 mars 2026, suivi d'une conférence le 1er avril. Détails disponibles sur leur site web Résultats Financiers Biotechnologie Conférence Téléphonique NANOBIOTIX
PRESS RELEASE published on 03/26/2026 at 21:15, 4 months 19 days ago NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026 Nanobiotix to announce fourth quarter and full year 2025 operational and financial update on March 31, 2026. Conference call and webcast scheduled for April 1, 2026 Conference Call Webcast Financial Update NANOBIOTIX Late-clinical Stage Biotechnology
BRIEF published on 03/25/2026 at 15:16, 4 months 20 days ago NANOBIOTIX dément les rumeurs de prise de contrôle Biotechnologie NANOBIOTIX Rumeurs Nanoparticules Prise De Contrôle
BRIEF published on 03/25/2026 at 15:16, 4 months 20 days ago NANOBIOTIX répond aux spéculations médiatiques concernant d'éventuelles intentions de rachat Biotechnologie Nanotechnologie Spéculations De Rachat NANOBIOTIX Déclaration Publique
BRIEF published on 03/25/2026 at 15:16, 4 months 20 days ago NANOBIOTIX Responds to Media Speculation on Takeover Intentions Biotechnology Nanotechnology Takeover Speculation NANOBIOTIX Public Statement
Published on 08/15/2026 at 00:50, 12 hours 31 minutes ago Revive Therapeutics Reports Grant of Options
Published on 08/15/2026 at 00:15, 13 hours 6 minutes ago Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 13 hours 36 minutes ago AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:25, 13 hours 56 minutes ago NuRAN Wireless Closes $7.6 Million Financing
Published on 08/14/2026 at 23:00, 14 hours 21 minutes ago Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
Published on 08/15/2026 at 08:05, 5 hours 16 minutes ago SKYWORTH Solar to Launch SolaMate Balcony Solar System on Joybuy Germany on August 15
Published on 08/14/2026 at 18:15, 19 hours 6 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/14/2026 at 16:05, 21 hours 16 minutes ago GATORADE WELCOMES AITANA BONMATÍ TO TEAM GATORADE AHEAD OF THE NEW FOOTBALL SEASON
Published on 08/13/2026 at 18:00, 1 day 19 hours ago Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 3 days 19 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 3 days 19 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 4 days 19 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 4 days 19 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
